日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

WHO resumes hydroxycholorquine trial after 'threat' queried

By CHEN WEIHUA in Brussels | chinadaily.com.cn | Updated: 2020-06-04 08:40
Share
Share - WeChat
WHO Director-General Tedros Adhanom Ghebreyesus. [Photo/Agencies]

The World Health Organization, or WHO, said on Wednesday that it will resume trials of anti-malaria drug hydroxycholorquine as a potential treatment of COVID-19 after having previously announced a temporary pause early last week.

WHO Director-General Tedros Adhanom Ghebreyesus said the executive group of the Solidarity Trial program had decided to implement a temporary pause last week because of concerns raised about the safety of the drug. The decision was taken as a precaution while the safety data was reviewed, something that has since been done by the Trial's Data Safety and Monitoring Committee.

"On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol," Tedros told a virtual news conference from Geneva.

"The executive group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine."

He said the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.

The WHO's announcement of a temporary halt, made on May 25, came after a paper published in medical journal The Lancet showed that people taking hydroxychloroquine were at higher risk of death and heart problems than those who were not.

The drug has been in the spotlight after United States President Donald Trump publicly promoted it at various occasions. Weeks ago, Trump claimed he was taking it as a precaution, but he said last week that he had finished taking it.

The Lancet articles have now turned out to be problematic. A report on ScienceMag.org on Tuesday said that the Lancet results have begun to unravel, and Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur investigators.

They have pointed out many red flags in the Lancet paper, including the number of patients involved and details about their demographics and prescribed dosing that seem implausible.

"It began to stretch and stretch and stretch credulity," Nicholas White, a malaria researcher at Mahidol University in Bangkok, was quoted as saying.

On Wednesday, Soumya Swaminathan, the WHO's chief scientist, said she hopes the ongoing trial will continue until it has definite answers whether it works or not.

"That can only be done through well conducted randomized trials," she said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 噜噜噜噜精品视频在线观看 | 亚洲天堂欧美在线 | 欧美激情专区 | 亚洲中午字幕 | 国产一级特黄aa大片免费 | 最新国产精品 | 欧美精品一区在线 | 日本熟妇毛茸茸xxxxx | 一区二区三区国产 | 精品视频在线播放 | 另类五月天 | 九热精品 | 亚洲精品亚洲人成人网 | 国产第一页浮力 | 亚洲免费视频在线观看 | 国产免费小视频在线观看 | 久久久精品网 | 一区二区日韩精品 | 一区二区三区四区免费看 | 国产男女免费完整版视频 | 二区国产 | 高清激情小视频在线观看 | 日本高清中文字幕一区二区三区 | 精品久久一区二区 | 欧美伦理一区 | 综合九九 | 一区二区视频在线观看 | 久久青 | 视频一区二区在线观看 | 久久精品国产99国产精品澳门 | 亚洲日本在线观看视频 | 香蕉18xxoo欧美夜视频 | 欧美a在线 | 国产视频资源在线观看 | 宅男lu666噜噜噜在线观看 | 久久狠狠| 国产精品久久99 | 午夜视频一区 | 亚洲综合无码一区二区 | 久久精品久久精品久久 | 国产亚洲精品国产 |